Sort
51,593 grants matching “hepatitis”
Harnessing the latent heat of saline evaporation for safe and effective endovascular therapeutic organ cooling
$443,850David F Kallmes · Mayo Clinic Rochester · R21 · FY2023 · NS
FOCUS Data Coordinating Center
$443,837Michael L. Terrin · University Of Maryland Baltimore · U01 · FY2006 · HL
Hormonal regulation of LDL receptor trafficking
$443,828Alan R. Saltiel · University Of California, San Diego · R01 · FY2023 · DK
Group testing for infectious disease detection
$443,828Christopher R Bilder · University Of Nebraska Lincoln · R01 · FY2021 · AI
Hormonal regulation of LDL receptor trafficking
$443,828Alan R. Saltiel · University Of California, San Diego · R01 · FY2021 · DK
Hormonal regulation of LDL receptor trafficking
$443,828Alan R. Saltiel · University Of California, San Diego · R01 · FY2022 · DK
In Utero Stem Cell Transplantation for Hemophilia A
$443,822Graca Duarte Almeida-Porada · University Of Nevada Reno · R01 · FY2006 · HL
Restoring Immune Tolerance in a Model of Multiple Sclerosis
$443,776Geoffrey D Keeler · University Of Florida · R01 · FY2025 · AI
HMGB1 as Link Between Hepatocellular Injury and HCC
$443,761Robert F. Schwabe · Columbia University Health Sciences · R01 · FY2020 · CA
HMGB1 as Link Between Hepatocellular Injury and HCC
$443,761Robert F. Schwabe · Columbia University Health Sciences · R01 · FY2017 · CA
HMGB1 as Link Between Hepatocellular Injury and HCC
$443,761Robert F. Schwabe · Columbia University Health Sciences · R01 · FY2018 · CA
Sensitive and quantitative point-of-care viral load testing on paper
$443,750Hadi Shafiee · Brigham And Women'S Hospital · R01 · FY2020 · AI
Non-immunosuppressive Sanglifehrin Analogs as Therapeutic Agents for Viral Hepatitis-induced Liver Damage Development
$443,750Philippe Andre Gallay · Scripps Research Institute, The · R01 · FY2021 · AI
Non-immunosuppressive Sanglifehrin Analogs as Therapeutic Agents for Viral Hepatitis-induced Liver Damage Development
$443,750Philippe Andre Gallay · Scripps Research Institute, The · R01 · FY2022 · AI
Non-immunosuppressive Sanglifehrin Analogs as Therapeutic Agents for Viral Hepatitis-induced Liver Damage Development
$443,750Philippe Andre Gallay · Scripps Research Institute, The · R01 · FY2023 · AI
Non-immunosuppressive Sanglifehrin Analogs as Therapeutic Agents for Viral Hepatitis-induced Liver Damage Development
$443,750Philippe Andre Gallay · Scripps Research Institute, The · R01 · FY2020 · AI
Sensitive and quantitative point-of-care viral load testing on paper
$443,750Hadi Shafiee · Brigham And Women'S Hospital · R01 · FY2019 · AI
Sensitive and quantitative point-of-care viral load testing on paper
$443,750Hadi Shafiee · Brigham And Women'S Hospital · R01 · FY2018 · AI
Etiology and Treatment of Biliary Atresia and Idiopathic Neonatal Hepatitis
$443,740Ronald J Sokol · University Of Colorado Denver · U01 · FY2007 · DK
Development of Advanced C-arm Cone-Beam CT for the Treatment of Liver Cancer
$443,731Xiaochuan Pan · University Of Chicago · R01 · FY2016 · CA
Evolution of CD8+ TCR affinity during chronic viral infection
$443,674Brian D. Evavold · Emory University · R01 · FY2015 · AI
Gaining Metabolic Insight in Older Men undergoing Androgen Deprivation Therapy for Prostate Cancer
$443,641Shehzad Basaria · Brigham And Women'S Hospital · R01 · FY2019 · CA
Factors Determining Bisphenol A Disposition in Human Infants
$443,579D Gail McCarver · Medical College Of Wisconsin · R01 · FY2011 · ES
Assessment of hyperthermia-based multimodal approach for hepatic colorectal metastases
$443,574Yong J Lee · Cedars-Sinai Medical Center · R01 · FY2023 · CA
Trans-NIH RNAi Facility (TNRF)
$443,543Anton Simeonov · National Center For Advancing Translational Sciences · ZIC · FY2016 · TR